Advertisement

Advertisement
Issues in Oncology

Health-Care Fraud Prosecutions Are on the Rise

Prosecuting health-care fraud is a top priority for the U.S. Department of Justice (DOJ) and other federal government agencies. After all, the government earns a $6 return for every $1 that it spends on enforcement. In December 2018, the DOJ announced that it had obtained more than $2.5 billion in settlements and judgments from civil cases involving health-care fraud in the fiscal year ending September 30, 2018. In addition, the DOJ criminally prosecuted hundreds of health-care fraud cases over this period. At the same time, the U.S. Department of Health and Human Services Office of the Inspector General excluded thousands of providers and entities from participating in and billing Medicare, Medicaid, and other federal health-care programs.

Integrative Oncology

Omega-3 Fatty Acids

Omega-3 fatty acids (omega-3s) play an important role in many physiologic processes. They are acquired through diet or via supplementation due to the inability of the human body to synthesize them. Fatty fish, some plants, and nut oils are rich in omega-3s. Dietary supplements include fish oil, krill oil, cod liver oil, and algal oil, available in the form of capsules or soft gels. They are widely used for depression, to lower cholesterol, to boost memory, as well as to reduce inflammation and the risk of heart attack.

Lymphoma

Update on Newer Treatments in Non-Hodgkin Lymphomas

As part of The ASCO Post’s continued coverage of the 2018 American Society of Hematology (ASH) Annual Meeting & Exposition, here is an update on several different studies on new therapeutics in non-Hodgkin lymphomas (NHLs), including follicular lymphoma, diffuse large B-cell lymphoma (DLBCL), primary mediastinal B-cell lymphoma, and CD30-positive peripheral T-cell lymphoma.


Advertisement
Breast Cancer

We Need Better Screening Methods for Detecting Breast Cancer

My breast cancer was probably a decade in the making, although I only became aware that there might be a problem in 2014, when I noticed some slight pain in my left breast. A routine mammogram and ultrasound found benign cysts in my dense breasts, which most likely explained the pain, I was told, but nothing more troubling than that. In 2015, I had another routine mammogram, still complaining about the pain in my left breast; once again, I was given the all-clear. The following year, the radiology center started offering three-dimensional mammogram imaging, which is reported to be more accurate at detecting breast cancer than two-dimensional digital mammograms; again, the test found no suspicious signs of cancer.

Prostate Cancer
Immunotherapy

Viral Vector–Based Immunotherapy in Metastatic Castration-Resistant Prostate Cancer

In a phase III trial reported in the Journal of Clinical Oncology, Gulley et al found that PROSTVAC, a viral vector-based immunotherapy, did not improve overall survival or 6-month event-free survival vs placebo in patients with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer.

Advertisement




More Top Stories

Breast Cancer

Eva M. Ciruelos, MD, PhD, on HER2-Positive Breast Cancer: Results From the PATRICIA Trial

Perlmutter Cancer Center Receives Anonymous $75 Million Gift to Create Center for Blood Cancers

NYU Langone Health’s Laura and Isaac Perlmutter Cancer Center recently announced a philanthropic gift to establish a Center for Blood Cancers. The center will house a new program for multiple myeloma care and research, along with NYU Langone Health’s other blood cancer programs. It will also...

Advertisement

Strategies to Increase Inclusion of Racial and Ethnic Minorities in Clinical Trials

As reported in the Journal of Oncology Practice by Regnante et al, the National Minority Quality Forum and Sustainable Healthy Communities Diverse Cancer Communities Working Group identified strategies employed by U.S. Cancer Centers of Excellence that have resulted in increased inclusion of racial ...

Pancreatic Cancer

Andrew X. Zhu, MD, PhD, on Pancreatic Cancer: Results From the Prep-02/JSAP-05 Trial

Perlmutter Cancer Center Receives Anonymous $75 Million Gift to Create Center for Blood Cancers

NYU Langone Health’s Laura and Isaac Perlmutter Cancer Center recently announced a philanthropic gift to establish a Center for Blood Cancers. The center will house a new program for multiple myeloma care and research, along with NYU Langone Health’s other blood cancer programs. It will also...

Issues in Oncology

10 Patient-Centered Principles for More Conservative Cancer Diagnosis

Although diagnostic errors date back to antiquity, in recent years, they have begun to receive attention as an important patient safety issue. This culminated in the National Academy of Medicine’s 2015 landmark report, which concluded that most people in the United States would experience ...

Use of Specialized PET/CT to Assess Estrogen Receptor Status in Recurrent or Metastatic Breast Cancer

In a Korean study reported in The Lancet Oncology, Chae et al found that 16α-[18F]fluoro-17β-oestradiol (18F-FES) positron-emission tomography/computed tomography (PET/CT) may permit accurate reevaluation of estrogen receptor status in recurrent or metastatic breast cancer when repeat...

Sumanta K. Pal, MD, on Clinical Cancer Advances: The 14th Annual Report

Otis W. Brawley, MD, Joins Faculty of Johns Hopkins Kimmel Cancer Center

Otis W. Brawley, MD, an authority on cancer screening and prevention who served as Chief Medical and Scientific Officer for the American Cancer Society and Director of the Georgia Cancer Center at Grady Memorial Hospital in Atlanta, has been named a Bloomberg Distinguished Professor at Johns...

Advertisement

FDA Pipeline: Assay Approval, Breakthrough Designations for AI Technology and CLL, and More

In the past week, the U.S. Food and Drug Administration (FDA) approved a companion diagnostic assay, granted Breakthrough Device and Breakthrough Therapy designations, and extended the review period of a proposed treatment. The agency also published four draft guidances and one final guidance...